BEAT

D. Boral Capital downgraded HeartBeam from Buy to Hold

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

8-K - HeartBeam, Inc. (0001779372) (Filer)

Offering was led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it has closed its underwritten public offering of 12,500,000 shares of common stock for total gross proceeds of $10 million before deducting underwriting discounts, commissions, and offering expenses. The closing of the offering occurred on April 16, 2026. The offering was led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing i

424B5 - HeartBeam, Inc. (0001779372) (Filer)

Offering is being led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, le

424B5 - HeartBeam, Inc. (0001779372) (Filer)

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). All of the securities to be sold in the proposed offering will be offered by HeartBeam. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system,

B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

D. Boral Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $5.00

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)

4 - HeartBeam, Inc. (0001779372) (Issuer)